Genetic susceptibility variants associated with colorectal cancer prognosis
Por:
Abuli, A, Lozano, JJ, Rodriguez-Soler, M, Jover, R, Bessa, X, Munoz, J, Esteban-Jurado, C, Fernandez-Rozadilla, C, Carracedo, A, Ruiz-Ponte, C, Cubiella, J, Balaguer, F, Bujanda, L, Rene, JM, Clofent, J, Morillas, JD, Nicolas-Perez, D, Xicola, RM, Llor, X, Pique, JM, Andreu, M, Castells, A, Castellvi-Bel, S, Martin, M, Spanish Gastroenterological Assoc
Publicada:
1 oct 2013
Resumen:
Colorectal cancer (CRC) is the second leading cause of cancer-related death among men and women in Western countries. Once a tumour develops, a differentiated prognosis could be determined by lifestyle habits or inherited and somatic genetic factors. Finding such prognostic factors will be helpful in order to identify cases with a shorter survival or at a higher risk of recurrence that may benefit from more intensive treatment and follow-up surveillance. Sixteen CRC genetic susceptibility variants were directly genotyped in a cohort of 1235 CRC patients recruited by the EPICOLON Spanish consortium. Univariate Cox and multivariate regression analyses were performed taking as primary outcomes overall survival (OS), disease-free survival and recurrence-free interval. Genetic variants rs9929218 at 16q22.1 and rs10795668 at 10p14 may have an effect on OS. The G allele of rs9929218 was linked with a better OS [GG genotype, genotypic model: hazard ratio (HR) 0.65, 95% confidence interval (CI) 0.450.93, P 0.0179; GG/GA genotypes, dominant model: HR 0.66, 95% CI 0.470.94, P 0.0202]. Likewise, the G allele of rs10795668 was associated with better clinical outcome (GG genotype, genotypic model: HR 0.73, 95% CI 0.531.01, P 0.0570; GA genotype, genotypic model: HR 0.66, 95% CI 0.470.92, P 0.0137; GG/GA genotypes, dominant model: HR 0.68, 95% CI 0.500.94, P 0.0194). In conclusion, CRC susceptibility variants rs9929218 and rs10795668 may exert some influence in modulating patients survival and they deserve to be further tested in additional CRC cohorts in order to confirm their potential as prognosis or predictive biomarkers.
Filiaciones:
Abuli, A:
Univ Barcelona, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Dept Gastroenterol,Hosp Clin, Inst Invest Biomed August Pi & Sunyer IDIBAPS, E-08036 Barcelona, Catalonia, Spain
Pompeu Fabra Univ, Dept Gastroenterol, Hosp Mar IMIM, Hosp Mar Med Res Ctr, Barcelona 08018, Catalonia, Spain
Lozano, JJ:
Univ Barcelona, Ctr Invest Biomed Red Enfermedades Hepat & Digest, E-08036 Barcelona, Catalonia, Spain
Rodriguez-Soler, M:
Hosp Gen Alacant, Dept Gastroenterol, Alicante 03010, Spain
Jover, R:
Hosp Gen Alacant, Dept Gastroenterol, Alicante 03010, Spain
Bessa, X:
Pompeu Fabra Univ, Dept Gastroenterol, Hosp Mar IMIM, Hosp Mar Med Res Ctr, Barcelona 08018, Catalonia, Spain
Munoz, J:
Univ Barcelona, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Dept Gastroenterol,Hosp Clin, Inst Invest Biomed August Pi & Sunyer IDIBAPS, E-08036 Barcelona, Catalonia, Spain
Esteban-Jurado, C:
Univ Barcelona, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Dept Gastroenterol,Hosp Clin, Inst Invest Biomed August Pi & Sunyer IDIBAPS, E-08036 Barcelona, Catalonia, Spain
Fernandez-Rozadilla, C:
Univ Santiago de Compostela, Galician Publ Fdn Genom Med FPGMX, Ctr Invest Biomed Red Enfermedades Raras CIBERER, Genom Med Grp,Hosp Clin, Santiago De Compostela 15704, Galicia, Spain
Carracedo, A:
Univ Santiago de Compostela, Galician Publ Fdn Genom Med FPGMX, Ctr Invest Biomed Red Enfermedades Raras CIBERER, Genom Med Grp,Hosp Clin, Santiago De Compostela 15704, Galicia, Spain
Ruiz-Ponte, C:
Univ Santiago de Compostela, Galician Publ Fdn Genom Med FPGMX, Ctr Invest Biomed Red Enfermedades Raras CIBERER, Genom Med Grp,Hosp Clin, Santiago De Compostela 15704, Galicia, Spain
Cubiella, J:
Complexo Hosp Ourense, Dept Gastroenterol, Orense 32005, Spain
Balaguer, F:
Univ Barcelona, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Dept Gastroenterol,Hosp Clin, Inst Invest Biomed August Pi & Sunyer IDIBAPS, E-08036 Barcelona, Catalonia, Spain
Bujanda, L:
Univ Basque Country, Dept Gastroenterol, Hosp Donostia, Networked Biomed Res Ctr Hepat & Digest Dis CIBER, San Sebastian 20014, Spain
Rene, JM:
Hosp Arnau Vilanova, Dept Gastroenterol, Lleida 25198, Spain
Clofent, J:
Hosp Meixoeiro, Dept Gastroenterol, Vigo 36200, Spain
Morillas, JD:
Hosp Clin Madrid, Dept Gastroenterol, Madrid 28040, Spain
Nicolas-Perez, D:
Hosp Univ Canarias, Dept Gastroenterol, Santa Cruz De Tenerife 38320, Canarias, Spain
Xicola, RM:
Univ Illinois, Sect Digest Dis & Nutr, Chicago, IL 60607 USA
Llor, X:
Univ Illinois, Sect Digest Dis & Nutr, Chicago, IL 60607 USA
Pique, JM:
Univ Barcelona, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Dept Gastroenterol,Hosp Clin, Inst Invest Biomed August Pi & Sunyer IDIBAPS, E-08036 Barcelona, Catalonia, Spain
Andreu, M:
Pompeu Fabra Univ, Dept Gastroenterol, Hosp Mar IMIM, Hosp Mar Med Res Ctr, Barcelona 08018, Catalonia, Spain
Castells, A:
Univ Barcelona, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Dept Gastroenterol,Hosp Clin, Inst Invest Biomed August Pi & Sunyer IDIBAPS, E-08036 Barcelona, Catalonia, Spain
Castellvi-Bel, S:
Univ Barcelona, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Dept Gastroenterol,Hosp Clin, Inst Invest Biomed August Pi & Sunyer IDIBAPS, E-08036 Barcelona, Catalonia, Spain
Martin, M:
Institut d’Investigació Biomèdica Sant Pau (IIB SANT PAU), Sant Quintí 77-79, 08041 Barcelona, Spain
Bronze
|